This placebo controlled, double-blind study evaluated the efficacy and safety of lamivudine in patients with hepatitis B e antigen (HBeAg)-negative/hepatitis B virus (HBV) DNA-positive chronic hepatitis B. Patients were randomized to receive 100 mg lamivudine orally once daily for 52 weeks (n ؍ 60
Analysis of hepatitis B virus precore variants in hepatitis B e antibody-positive patients treated with prednisone plus interferon
✍ Scribed by J. M. Lopez-Alcorocho; M. Cabrerizo; J. Bartolome; T. Cotonat; V. Carren̄o
- Book ID
- 119836565
- Publisher
- John Wiley and Sons
- Year
- 1995
- Tongue
- English
- Weight
- 719 KB
- Volume
- 2
- Category
- Article
- ISSN
- 1352-0504
No coin nor oath required. For personal study only.
📜 SIMILAR VOLUMES
The objective of this study was to evaluate the role of hepatitis B virus (HBV) precore mutations in patients with anti-me-positive chronic hepatitis B with or without previous known HBe antigen (HBeAg) viremic phase, and to assess the potential implication of precore mutants in HBeAg-negative react
Precore defective HBV mutants may gradually prevail because of immune selection and explain spontaneous seroconversion from HBeAg to anti-HBe in HBV carriers. We have analyzed whether the presence of precore HBV mutants is a determinant of responsiveness to interferon-a therapy. Fifteen carriers (ni